NCT04275414View on ClinicalTrials.gov

Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 15, 2020

Primary Completion Date

April 5, 2020

Study Completion Date

May 2, 2020

Conditions
Coronavirus Infections
Interventions
DRUG

Bevacizumab Injection

Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min

Trial Locations (3)

250012

Qilu Hospital of Shandong University, Jinan

Unknown

Renmin Hospital of Wuhan University, Wuhan

Moriggia-Pelascini Gravedona Hospital, Gravedona

All Listed Sponsors
collaborator

Renmin Hospital of Wuhan University

OTHER

collaborator

Moriggia-Pelascini Gravedona Hospital

UNKNOWN

lead

Qilu Hospital of Shandong University

OTHER

NCT04275414 - Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter